Εμφανίζονται 1 - 20 Αποτελέσματα από 34 για την αναζήτηση '"ПАРОКСИЗМАЛЬНАЯ НОЧНАЯ ГЕМОГЛОБИНУРИЯ"', χρόνος αναζήτησης: 1,17δλ Περιορισμός αποτελεσμάτων
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
    Academic Journal
  8. 8
  9. 9
    Academic Journal

    Πηγή: Сборник статей

    Περιγραφή αρχείου: application/pdf

    Relation: Актуальные вопросы современной медицинской науки и здравоохранения: Материалы VI Международной научно-практической конференции молодых учёных и студентов, посвященной году науки и технологий, (Екатеринбург, 8-9 апреля 2021): в 3-х т.; http://elib.usma.ru/handle/usma/6438

    Διαθεσιμότητα: http://elib.usma.ru/handle/usma/6438

  10. 10
  11. 11
    Academic Journal

    Συνεισφορές: This article has been translated into English by M. Povorin and edited for English language and spelling by Enago, an editing brand of Crimson Interactive Inc.

    Πηγή: Fine Chemical Technologies; Vol 15, No 2 (2020); 77-85 ; Тонкие химические технологии; Vol 15, No 2 (2020); 77-85 ; 2686-7575 ; 2410-6593

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.finechem-mirea.ru/jour/article/view/1599/1654; https://www.finechem-mirea.ru/jour/article/view/1599/1661; https://www.finechem-mirea.ru/jour/article/downloadSuppFile/1599/151; https://www.finechem-mirea.ru/jour/article/downloadSuppFile/1599/176; Hill A., Platts P.J., Smith A. The incidence and prevalence of paroxysmal nocturnal hemoglobinuria (PNH) and survival of patients in Yorkshire. Blood. 2006;108(11):985. https://doi.org/10.1182/blood.V108.11.985.985; Pu J.J., Brodsky R.A. Paroxysmal nocturnal hemoglobinuria from bench to bedside. ClinTranslSci. 2011;4(3):219‐224. https://doi.org/10.1111/j.17528062.2011.00262.x; Devalet B., Mullier F., Chatelain B., Dogne J.M., Chatelain C. Pathophysiology, diagnosis, and treatment of paroxysmal nocturnal hemoglobinuria: a review. Eur. J. Haematol. 2015;95(3):190‐198. https://doi.org/10.1111/ejh.12543; Höchsmann B., Rojewski M., Schrezenmeier H. Paroxysmal nocturnal hemoglobinuria (PNH): higher sensitivity and validity in diagnosis and serial monitoring by flow cytometric analysis of reticulocytes. Ann. Hematol. 2011;90(8):887-899. https://doi.org/10.1007/s00277-011-1177-4; Brodsky R.A., Young N.S., Antonioli E. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008;111(4):1840-1847. https://doi.org/10.1182/blood-2007-06-094136; Tegla C.A., Cudrici C., Patel S. Membrane attack by complement: the assembly and biology of terminal complement complexes. Immunol. Res. 2011;51(1):45–60. https://doi.org/10.1007/s12026011-8239-5; Ricklin D., Hajishengallis G., Yang K., Lambris J.D. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 2010;11(9):785-797. https://doi.org/10.1038/ni.1923; Dubois E.A., Cohen A.F. Eculizumab. Br. J. Clin. Pharmacol. 2009;68(3):318-319. https://doi.org/10.1111/j.1365-2125.2009.03491.x; Khedraki R., Noor Z., Rick J. The Most Expensive Drug in the World: To Continue or Discontinue, That Is the Question. Fed. Pract. 2016;33(7):22-28. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366567/; Harder M. J., Kuhn N., Schrezenmeier H., et al. Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation. Blood. 2016;129(8):970-980. https://doi.org/10.1182/blood-2016-08-732800; Kelly R. J., Höchsmann B., Szer J., et al. Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria. N. Engl. J. Med. 2015;373(11):1032-1039. https://doi.org/10.1056/NEJMoa1502950; Wehling C., Amon O., Bommer M. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders. Clin. Exp. Immunol. 2016;187(2):304-315. https://doi.org/10.1111/cei.12890; Validation of Analytical Procedures: Text and Methodology Q2(R1). In: International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use. Geneva. 2005;6-13. https://www.gmp-compliance.org/guidemgr/files/Q2(R1).pdf; Tijssen P. Practice and Theory of Enzyme Immunoassays. Canada: Elsevier Science; 1985. 548 p.; Исакова О.П., Тарасевич Ю.Ю. Обработка и визуализация данных физических экспериментов с помощью пакета Origin. Учебно-методическое пособие. Астрахань: Издательство ОГОУ ДПО «АИПКП»; 2007. 67 c. [Isakova O.P., Tarasevich Yu.Yu. Obrabotka i vizualizatsiya dannykh fizicheskikh eksperimentov s pomoshchʼyu paketa Origin (Processing and visualization of physical experiment data using the Origin package). Educational and methodological guide. Astrakhan: DPO AIPKP Publ.; 2007; 67 p. (in Russ.).]; Guideline on similar biological medicinal products. Committee for Medicinal Products for Human Use; 2014. 16 p. URL: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-rev1_en.pdf

  12. 12
  13. 13
    Academic Journal

    Πηγή: Russian Journal of Pediatric Hematology and Oncology; Том 3, № 4 (2016); 81-84 ; Российский журнал детской гематологии и онкологии (РЖДГиО); Том 3, № 4 (2016); 81-84 ; 2413-5496 ; 2311-1267 ; 10.17650/2311-1267-2016-3-4

    Περιγραφή αρχείου: application/pdf

    Relation: https://journal.nodgo.org/jour/article/view/267/267; Кулагин А.Д., Лисуков И.А., Птушкин В.В. и др. Национальные клинические рекомендации по диагностике и лечению пароксизмальной ночной гемоглобинурии. Клиническая фармакология и терапия 2015;24(1):18–26. [Kulagin A.D., Lisukov I.A., Ptushkin V.V. et al. National clinical guidelines for the diagnosis and treatment of paroxysmal nocturnal hemoglobinuria. Klinicheskaya farmakologiya i terapiya = Clinical Pharmacology and Therapy 2015;24(1):18–26. (In Russ.)].; Hillmen P., Lewis S.M., Bessler M. et al. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995;333:1253–8.; Новичкова Г.А., Петрова У.Н., Калинина И.И., Масчан А.А. Пароксизмальная ночная гемоглобинурия у детей (обзор литературы). Доктор.ру 2016;5(122):15–20. [Novichkova G.A., Petrova U.N., Kalinina I.I., Maschan A.A. Paroxysmal nocturnal hemoglobinuria in children: literature review. Doktor.ru = Doctor.ru 2016;5(122):15–20. (In Russ.)].; Van den Heuvel-Eibrink M.M., Bredius R.G., te Winkel M.L. et al. Childhood paroxysmal nocturnal haemoglobinuria (PNH), a report of 11 cases in the Netherlands. Br J Haematol 2005;128: 571–77.; Curran K.J., Kernan N.A., Prockop S.E. et al. Paroxysmal nocturnal hemoglobinuria in pediatric patients. Pediatr Blood Cancer 2012;59:525–9.; Ware R.E., Hall S.E., and Rosse W.F. Paroxysmal nocturnal hemoglobinuria with onset in childhood and adolescence. N Engl J Med 1991;325:991–6.; Timeus F., Crescenzio N., Foglia L. et al. Paroxysmal nocturnal haemoglobinuria from the prespective of paediatric haematologists. Curr Drug Targets 2016 Apr 1. [Epub ahead of print].; Saso R., Marsh J., Cevreska L. et al. Bone marrow transplants for paroxysmal nocturnal haemoglobinuria. Br J Haematol 1999;104:392–6.; de Latour R.P., Schrezenmeier H., Bacigalupo A. et al. Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria. Haematologica 2012;97(11):1666–73.; Reiss U.M., Schwartz J., Sakamoto K.M. et al. Efficacy and safety of eculizumab in children and adolescents with paroxysmal nocturnal hemoglobinuria. Pediatr Blood Cancer 2014;61(9):1544–50.; https://journal.nodgo.org/jour/article/view/267

  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20